Barclays PLC Has $999,000 Stock Position in Liquidia Co. (NASDAQ:LQDA)

Barclays PLC increased its stake in Liquidia Co. (NASDAQ:LQDA) by 265.0% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 99,984 shares of the company’s stock after purchasing an additional 72,591 shares during the quarter. Barclays PLC’s holdings in Liquidia were worth $999,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. BNP Paribas Financial Markets lifted its stake in Liquidia by 735.1% in the third quarter. BNP Paribas Financial Markets now owns 140,190 shares of the company’s stock valued at $1,402,000 after acquiring an additional 123,402 shares during the last quarter. Whitefort Capital Management LP lifted its stake in Liquidia by 119.8% in the 3rd quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock valued at $17,020,000 after purchasing an additional 927,546 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Liquidia by 144.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company’s stock worth $3,903,000 after purchasing an additional 230,820 shares during the period. Sapient Capital LLC acquired a new position in Liquidia during the third quarter worth approximately $1,336,000. Finally, Marshall Wace LLP bought a new stake in Liquidia in the second quarter valued at approximately $545,000. 64.54% of the stock is owned by institutional investors.

Insider Activity at Liquidia

In other news, CFO Michael Kaseta sold 23,370 shares of the company’s stock in a transaction on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total transaction of $275,298.60. Following the completion of the sale, the chief financial officer now directly owns 401,755 shares in the company, valued at approximately $4,732,673.90. This represents a 5.50 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Rajeev Saggar sold 2,526 shares of the firm’s stock in a transaction on Friday, October 18th. The stock was sold at an average price of $11.19, for a total value of $28,265.94. Following the completion of the transaction, the insider now owns 204,857 shares in the company, valued at $2,292,349.83. The trade was a 1.22 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 73,581 shares of company stock worth $864,565. Company insiders own 30.10% of the company’s stock.

Liquidia Stock Down 3.4 %

Shares of NASDAQ:LQDA opened at $11.36 on Wednesday. Liquidia Co. has a 12-month low of $8.26 and a 12-month high of $16.99. The company’s 50 day moving average price is $11.20 and its two-hundred day moving average price is $11.01. The firm has a market cap of $961.48 million, a PE ratio of -6.97 and a beta of 0.23.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on LQDA. Scotiabank assumed coverage on Liquidia in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 target price on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price objective on shares of Liquidia in a report on Thursday, January 9th. Wells Fargo & Company started coverage on shares of Liquidia in a research note on Friday, December 20th. They set an “overweight” rating and a $20.00 target price for the company. Lifesci Capital started coverage on shares of Liquidia in a research note on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and set a $29.00 price objective on shares of Liquidia in a research report on Thursday, November 14th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $25.38.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).